Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The tendency within the weekly time frame is positive above the technical support level at 74.63 USD
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • Based on current prices, the company has particularly high valuation levels.
Ratings chart
Sector Specialty & Advanced Pharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
ABBVIE52.36%152 953
MERCK KGAA-11.15%13 516
KYOWA HAKKO KIRIN CO LTD28.31%10 547
JAZZ PHARMACEUTICALS PLC22.59%8 331
ZHANGZHOU PIENTZEHUANG PHAR..37.39%5 735
CONVATEC GROUP-11.29%5 528
ADVANCED ACCELERATOR APPLIC..--.--%3 604
INDIVIOR23.36%3 556
BETTA PHARMACEUTICALS CO LT..--.--%3 505
YUHAN CORP--.--%2 282
MALLINCKRODT PLC-57.35%2 119
SUPERNUS PHARMACEUTICALS IN..48.71%1 956
AIMMUNE THERAPEUTICS INC66.75%1 738
REPLIGEN CORPORATION13.89%1 549
-
THERAPEUTICSMD INC0.52%1 355
STALLERGENES GREER28.67%931
More Results
Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,71%
P/E ratio 2017 20,69
P/E ratio 2018 16,31
EV / Sales 2017 6,42x
EV / Sales 2018 5,68x
Capitalization 153 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing -
Middle Term Timing -
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABBVIE
Duration : Period : Day
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Duration : Period : Week
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders